

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date:	October 21, 2015
Revision date:	January 21, 2020, May 19, 2020, July 1, 2024

Ofev® (nintedanib)

LENGTH OF AUTHORIZATION: Up to 6 months

REVIEW CRITERIA:

- Patient must be ≥ 18 years old.
- Patient must obtain a liver function test prior to starting treatment.
- Must be prescribed or in consultation with a pulmonologist.

Idiopathic Pulmonary Fibrosis

- Confirmation of idiopathic pulmonary fibrosis through exclusions of other known causes of interstitial lung disease: Domestic and occupational environmental exposures, drug toxicity or connective tissue disease.
- Confirmation of diagnosis via lung biopsy for idiopathic pulmonary fibrosis diagnosis **OR** high-resolution computed tomography (HRCT).
- Documented pulmonary function tests within the past 60 days reflecting Forced Vital Capacity (FVC) $\geq 50\%$.
- Baseline percent predicted diffusing capacity of the lung for carbon monoxide is $\geq 30\%$ for idiopathic pulmonary fibrosis.
- Documentation submitted that the patient is a nonsmoker or has been abstinent for at least six weeks.

Systemic Sclerosis-Associated Interstitial Lung Disease

- Confirmation of systemic sclerosis-associated interstitial lung disease.
- Documentation submitted that the patient is a nonsmoker or has been abstinent for at least six weeks.
- Confirmation of diagnosis via high resolution computed tomography (HRCT).
- Documented pulmonary function tests within the past 60 days reflecting Forced Vital Capacity (FVC) $\geq 40\%$.

Chronic Fibrosing Interstitial Lung Diseases

- Confirmation of chronic fibrosing interstitial lung diseases with a progressive phenotype.
- **Confirmation of diagnosis via high resolution computer tomography (HRCT) scan showing fibrosis affecting $\geq 10\%$ of lungs.**
- Documentation submitted that the patient is a nonsmoker or has been abstinent for at least six weeks.
- Documented pulmonary function test within the past 60 days reflecting Forced Vital Capacity (FVC) $\geq 45\%$ of predicted.
- Baseline percent predicted diffusing capacity of the lung for carbon monoxide (DLCO) between 30-79%.

CONTINUATION OF THERAPY:

- **Patient met initial review criteria.**
- **Patient has not experienced any treatment-restricting adverse effects.**

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date:	October 21, 2015
Revision date:	January 21, 2020, May 19, 2020, July 1, 2024

- **Dosing is appropriate as per labeling or is supported by compendia.**
- Documentation of improvement or effectiveness of therapy (< 200ml decrease in FVC or <10% decline in percent predicted FVC) for idiopathic pulmonary fibrosis.
- Documentation of improvement or effectiveness of therapy for systemic sclerosis-associated interstitial lung disease.
- Documentation that the rate of decline of lung function has slowed for chronic fibrosing interstitial lung diseases.
- Clinical documentation that the recipient is tobacco free.

DOSING & ADMINISTRATION:

- **Refer to product labeling <https://www.accessdata.fda.gov/scripts/cder/daf/>**
- **Available as a 100 mg and 150 mg capsules**